179 related articles for article (PubMed ID: 11383211)
21. [A case of recurrent breast cancer successfully treated with docetaxel].
Nakagawa T; Kudo T; Onuki M; Seto T; Kamata S; Kiyosawa Y; Ogawa J
Gan To Kagaku Ryoho; 2001 Mar; 28(3):383-5. PubMed ID: 11265409
[TBL] [Abstract][Full Text] [Related]
22. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
[TBL] [Abstract][Full Text] [Related]
24. [Weekly paclitaxel therapy for metastatic breast cancer].
Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
[TBL] [Abstract][Full Text] [Related]
25. [Treatment outcomes with vinorelbine for metastatic breast cancer patients previously treated with both doxorubicin and docetaxel].
Tashiro H; Sonoda K; Ohshiro T; Ohta M; Yamamura S; Ishikawa T; Itasaka H; Matsusaka T; Kume K
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1397-401. PubMed ID: 11681247
[TBL] [Abstract][Full Text] [Related]
26. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel: a new defence in the management of breast cancer.
Piccart M
Anticancer Drugs; 1995 Jul; 6 Suppl 4():7-11. PubMed ID: 8745348
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel administered on a weekly basis for metastatic breast cancer.
Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
[TBL] [Abstract][Full Text] [Related]
29. [Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].
Nagai S; Toi M; Kuroi K; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2037-42. PubMed ID: 10584568
[TBL] [Abstract][Full Text] [Related]
30. Treatment of patients resistant to anthracycline therapy.
Ravdin PM
Anticancer Drugs; 1996 Aug; 7 Suppl 2():13-6. PubMed ID: 8862704
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Yonemori K; Katsumata N; Uno H; Matsumoto K; Kouno T; Tokunaga S; Yamanaka Y; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2005 Feb; 89(3):237-41. PubMed ID: 15754121
[TBL] [Abstract][Full Text] [Related]
32. [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)].
Mai M; Sakata Y; Kanamaru R; Kurihara M; Suminaga M; Ota J; Hirabayashi N; Taguchi T; Furue H
Gan To Kagaku Ryoho; 1999 Mar; 26(4):487-96. PubMed ID: 10097745
[TBL] [Abstract][Full Text] [Related]
33. Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel.
Ishitobi M; Shin E; Kikkawa N
Int J Clin Oncol; 2001 Feb; 6(1):55-8. PubMed ID: 11706529
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Suzuma T; Sakurai T; Yoshimura G; Umemura T; Tamaki T; Naito Y
Anticancer Drugs; 2000 Aug; 11(7):569-71. PubMed ID: 11036960
[TBL] [Abstract][Full Text] [Related]
35. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Kruijtzer CMF ; Verweij J; Schellens JH; Beijnen JH; Pronk L; Bo M; Lustig V; van Tinteren H; Mackay M; Ten Bokkel Huinink WW
Anticancer Drugs; 2000 Apr; 11(4):249-55. PubMed ID: 10898539
[TBL] [Abstract][Full Text] [Related]
37. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
38. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
39. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Alexandre J; Bleuzen P; Bonneterre J; Sutherland W; Misset JL; Guastalla J; Viens P; Faivre S; Chahine A; Spielman M; Bensmaïne A; Marty M; Mahjoubi M; Cvitkovic E
J Clin Oncol; 2000 Feb; 18(3):562-73. PubMed ID: 10653871
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
